clearance had occurred. As shown in this case, when rifampin and fentanyl are used concomitantly, the analgesic effect of fentanyl may be considerably reduced. Thus, an increase in fentanyl dosage needs to be considered.
case was reported to the Biotest Department of Drug Safety in April 2003 and has been investigated with great diligence. According to the requirements of German drug law, we have also informed our supervising governmental authority, the Paul-Ehrlich-Institut. The result of our investigation is as follows:
1. In our production and quality control records, we found no indication of any technical failure of the lot used in India (lot 155011).
No adverse drug reactions have been reported for this lot by other hospitals. 2. Varitect CP was diluted in 10 mL of distilled water. However, Varitect CP is a ready-for-use solution and must not be diluted; this is mentioned in the instructions for use. 3. Along with Varitect CP, the infants also received intramuscular vitamin K, intravenous ranitidine in 1 mL of distilled water, and intravenous acyclovir in 10 mL of distilled water. 4. The total volume of distilled water administered to the babies via the diluted drugs was >20 mL. The total blood volume of a newborn weighing around 2000 g is approximately 160-180 mL. 5. Our research department investigated the effect of such dilution to whole blood. If undiluted Varitect CP is mixed with whole blood, no hemolysis occurs. However, if it is mixed with distilled water, hemolysis is induced. In view of these facts, we came to the conclusion that the death of the 2 babies was a result of hemolysis caused by the administration of >20 mL of distilled water with various drugs. The total blood volume was diluted by >10%. In our opinion, the death of the 2 infants was caused by inappropriate actions of the physician and is not suspected to be an adverse drug reaction.
Because Bhambhani et al.'s letter does not report the full information about the case (eg, total volume of distilled water infused), we chose to present the assessment of Varitect CP's marketing authorization holder.
Both authors are employees of Biotest AG, the parent company of Biotest Pharma GmbH, the marketing authorization holder of Varitect CP. is not an indicator that the pharmaceutical manufacturer was deficient in good manufacturing practices. TRALI is a reaction between transfused antileukocyte antibodies and recipient granulocytes. The twins may have had the same genetic make-up and similar granulocyte antigens, causing both to react adversely. The manufacturer cannot be held responsible for this reaction. We wholeheartedly agree with Pabst and Dehnicke that technical failures in the manufacturing process are not to blame. TRALI is a diagnosis arrived after exclusion of other possibilities. The Naranjo score is an attempt to estimate the probability that the adverse reaction was caused by a drug. The twins we reported on died catastrophically with pulmonary hemorrhage within 5 minutes of each other, and within 15 minutes of receiving Varitect CP. Pabst and Dehnicke suggest 4 alternate possibilities, which need to be examined.
Rainer Pabst PhD

Head of Pharma Division
They suggest that vitamin K received by the babies 12 hours earlier, acyclovir received 8 hours earlier, or ranitidine received 5 hours earlier could have been culprits. Given the chronology of events, this seems unlikely. The Naranjo score for each of these is below 1 and so the association is doubtful.
The fourth suggestion is that the water used to dilute the drugs may have caused the deaths. Their letter says that 20 mL of water was used (10 mL with Varitect CP and 10 mL with acyclovir), and that experiments performed at Biotest found that this can induce hemolysis. There are notable inaccuracies here.
First, hemolysis is not the same thing as pulmonary hemorrhage. The twins in our original report died of pulmonary hemorrhage, not hemolysis and anemia. Secondly, 10 mL of water for injection with acyclovir had been given 8 hours previously. This would have been sufficient time for it to equilibrate within the body before Varitect CP was given.
Finally, regarding the dilution of acyclovir, this was diluted as per the manufacturer's instructions and administered to the babies slowly over 30 minutes. In a letter dated June 4, 2003 (forwarded to us for reply), Biotest suggested that the babies might have died because of the use of undiluted acyclovir. We wrote to reassure them about the dilution of acyclovir. Now they write that dilution, rather than the use of undiluted acyclovir, contributed to the deaths. This change in stance shows a lack of conviction and a desire to place blame anywhere but on Varitect CP.
Ultimately, TRALI still appears a strong candidate for the cause of the twins' death from pulmonary hemorrhage. The experiment by Biotest underlines this. Although it is not caused by defects in the manufacturing process, TRALI is more likely to occur with an intravenous preparation than with the standard intramuscular preparation. Comment: supratherapeutic response to ezetimibe administered with cyclosporine TO THE EDITOR: I read with interest the article by Koshman et al. 1 I agree, as mentioned in the article, that this particular patient appears to have had a "supratherapeutic" response to ezetimibe. However, I suspect that this response may not be due-or at least, not entirely-to the interaction with cyclosporine. As pointed out in the article, an interaction between ezetimibe and cyclosporine deemed to be clinically significant has been reported. However, the data concerning lipid alterations were not reported. A premarketing dose-ranging study of ezetimibe that included 243 subjects who received doses between 0.25 and 40 mg/day demonstrated a flattened dose-response curve. 2,3 Mean low-density lipoprotein cholesterol (LDL-C) was reduced by 9.9%, 12.6%, 16.4%, 18.7%, and 20.0% in the patients randomized to receive ezetimibe 0.25, 1, 5, 10, 20, and 40 mg, respectively, after 8 weeks of treatment.
Vikas Bhambhani DCH
Similarly, 190 patients were administered a structural analog (active metabolite) of ezetimibe (SCH 48461) with doses ranging from 1 to 400 mg. 4 Mean LDL-C reduction ranged from 0.6% to 15.5%. These data suggest that if cyclosporine had increased serum total ezetimibe or ezetimibe glucuronide within the range of the doses studied above, the LDL-C response in Koshman et al.'s 1 case would not be due to the drugdrug interaction.
An alternative hypothesis is that this patient is a hyper-absorber of cholesterol and, therefore, falls on the extreme end of the Gaussian curve for LDL-C responses to an inhibitor of cholesterol absorption. 5 These types of patients tend to have a lower rate of cholesterol synthesis and fall on the opposite end of the Gaussian curve for LDL-C responses to statins. In this case, 1 the patient's baseline LDL-C was 156 mg/dL when he was started on atorvastatin 10 mg/day. The dosage was gradually titrated to 60 mg/day, which resulted in an LDL-C level of 103 mg/dL. This represents an LDL-C change of only 34%, which was considerably less than expected based on the manufacturer's prescribing information (50% for 40 mg and 60% for 80 mg). 6 Thus, this patient had a less-thanexpected response to statin therapy. Ziajka et al. 7 demonstrated that the initial response to a statin predicted the subsequent response to the addition of ezetimibe (r = 0.77; p < 0.001). In this retrospective analysis, the patient's actual response was compared with predicted response (manufacturer's prescribing information) for the agent and dose used. The additional decrease in LDL-C after the addition of ezetimibe ranged from 6% to 60%. Patients who responded poorly to a statin had the largest reduction in LDL-C when ezetimibe was added. We have found similar results in a prospective, randomized study of ezetimibe and simvastatin that was designed to confirm data presented at the 2005 Annual Meeting of the American College of Clinical Pharmacy. 8 Patients in our study will be phenotyped for absorption efficiency in an effort to aid in a more suitable drug selection. This case provides a good opportunity to educate clinicians on the importance of variability in cholesterol absorption and synthesis on the observed response to lipid-lowering agents.
North America (California, in particular) have not been clearly elucidated as to their cause and require further study to understand the connection between the use of mifepristone and misoprostol for early abortion, and the alarming rate of severe bacterial infection leading to death. All the cases occurred through the vaginal application of misoprostol. The most recent recommendation by the Food and Drug Administration (FDA) underscores the particular attention that must be paid to the use of these drugs prior to their widespread, generalized use in developing countries, where the rate of bacterial infection is very high. In Africa, the high frequency of genital infections, along with poor medical care, may result in a significant number of deaths if the use and application of mifepristone and misoprostol are not reexamined. This is especially true in light of the increased use in Africa of spermicide, which enhances genital bacteria carriage. 2 A recent fatal case (in California) was that of my (Pr. Sicard) 34-yearold daughter, the mother of 2 children. Five days after taking mifepristone and misoprostol, which was taken vaginally 24 hours after the mifepristone, she died in just a few hours from an infection and septic shock. The day before her death, she experienced bleeding, severe abdominal pain, and dizziness; 2 days before, she presented all the signs of an adrenal insufficiency (ie, hypotension, extreme fatigue).
Three issues seem important: (1) The fatal consequence of the inhibition of adrenal reaction during an acute genital infection linked to the death of the embryo, if Clostridium is present. (2) The lack of specificity of symptoms 2 or 3 days after taking mifepristone and misoprostol. Abdominal pain and bleeding are common with this drug combination. Lack of awareness of the severity of the situation at this moment is dangerous. (3) Combining mifepristone with misoprostol through vaginal application is extremely common in Anglo-Saxon countries, and specifically indicated in North America. Vaginal application is prohibited in France, where misoprostol can be prescribed only in oral form, and it is contraindicated in case of infection. There are no reported cases of such life-threatening bacterial infections in France.
Lastly, would it be useful to systematically give an antibiotic one day prior, during, and after the absorption of mifepristone, to eradicate Clostridium, and give dexamethasone in case of suspicion of the beginning of septic shock?
The alarming rate of deaths in healthy, young women in North America must be carefully examined prior to the generalized use of these drugs in developing countries. Issues that remain unaddressed are (1) the relationship between the vaginal application of misoprostol relative to the cause of severe bacterial infection, leading to death; (2) the effect of spermicide or other intra-uterine device as a carriage for bacteria, increasing the likelihood of severe infection following the use of mifepristone and misoprostol; and (3) whether the FDA's recommendation for mifepristone and misoprostol must be further modified as it relates to the use of prophylactic antibiotics, to ensure against the risk of severe, lethal infection. 
Pr. Didier Sicard
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